The FDA has approved PD-L1 expression determined by immunohistochemistry as a companion diagnostic for anti-PD-1/PD-L1 antibody treatment in advanced non-small-cell lung cancer. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.